Targeting the expression or deacetylation activity of SIRT2 has been shown to benefit in several neurodegenerative diseases such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), but not shown benefit in CMT (Donmez & Outeiro, 2013). The gene discussed is SIRT2; the disease is neurodegenerative disease.